Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.48 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
| ▸ | TK2 | O00142 | 2/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CDA | P32320 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21683245 | 1.00 | PYGM (0.48) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL27708288 | 0.88 | PYGM (0.60) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL27618439 | 0.87 | PYGM (0.46) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL27810485 | 0.86 | ADORA2A (0.39) | PYGMMAPT | |
| SCHEMBL27760732 | 0.86 | PYGM (0.51) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL1067013 | 0.85 | PYGM (0.52) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL1932437 | 0.83 | PYGM (0.50) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL21458099 | 0.83 | PYGM (0.52) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL441977 | 0.81 | PYGM (0.48) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL20534354 | 0.81 | PYGM (0.48) | PYGMSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146073-A1 | T CELL RECEPTORS TARGETING MUTATED CDKN2A | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2026-05-28 | — | — | US | disclosed |
| US-12624104-B2 | Compositions and methods for treating cancer with anti-CD19 immunotherapy | LENTIGEN TECHNOLOGY, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250304965-A1 | DOUBLE-STRANDED RNA MOLECULE AND PHARMACEUTICAL USE THEREOF | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-10-02 | — | — | US | disclosed |
| US-20250017970-A1 | Reduced Expression of Sarm1 For Use In Cell Therapy | EMENDOBIO INC. | 2025-01-16 | — | — | US | disclosed |
| US-20250018040-A1 | ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2025-01-16 | — | — | US | disclosed |
| US-20240328947-A1 | SYSTEMS AND METHODS FOR IMPROVING PARTICLE PROCESSING | ULTIMA GENOMICS INC (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240299510-A1 | ANTIBODY-GUIDED PCSK9-MIMICKING IMMUNOGENS LACKING 9-RESIDUE SEQUENCE OVERLAP WITH HUMAN PROTEINS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240294665-A1 | ANTI-CD70 CHIMERIC ANTIGEN RECEPTORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC | 2024-09-05 | — | — | US | disclosed |
| US-20240108706-A1 | Compositions and Methods for Treating Cancer with Anti-CD22 Immunotherapy | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2024-04-04 | — | — | US | disclosed |
| US-20240067724-A1 | Compositions and Methods for Treating Cancer with Anti-CD19 Immunotherapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2024-02-29 | — | — | US | disclosed |
| US-20050246784-A1 | Method for identifying herbicidally active substances | METANOMICS GMBH & CO., KGAA (DE) | 2005-11-03 | — | — | US | disclosed |
| US-20050221460-A1 | Novel genetic products from ashbya gossypii, associated with the structure of the cell wall or the cytoskeleton | BASF AG | 2005-10-06 | — | — | US | disclosed |
| US-20050148761-A1 | Genetic products of ashbya gossypii, associated with transmembrane transport | BASF AKTIENGESELLSCHAFT (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20050118583-A1 | Novel genetic products of ashbya gossypii, associated with the mechanisms of signal transduction and especially with the improvement of vitamin b2 production | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-02 | — | — | US | disclosed |
| EP-1517695-A2 | OSTEOPONTIN, OLIGODENDROCYTES AND MYELINATION | Aventis Pharmaceuticals, Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20050053932-A1 | Novel stress-associated genetic products from ashbya gossypii | BASF AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
| EP-1427833-A1 | NOVEL NUCLEIC ACID SEQUENCES AND THEIR USE IN METHODS FOR ACHIEVING PATHOGEN RESISTANCE IN PLANTS | BASF Plant Science GmbH (DE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2004001014-A2 | OSTEOPONTIN, OLIGODENDROCYTES AND MYELINATION | AVENTIS PHARMACEUTICALS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003020939-A1 | NOVEL NUCLEIC ACID SEQUENCES AND THEIR USE IN METHODS FOR ACHIEVING PATHOGEN RESISTANCE IN PLANTS | BASF PLANT SCIENCE GMBH (DE) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002070002-A2 | METHODS FOR REGULATION OF IMMUNE RESPONSES TO CONDITIONS INVOLVING MEDIATOR-INDUCED PATHOLOGY | UNIVERSITE DE LAUSANNE (CH) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146073-A1 | T CELL RECEPTORS TARGETING MUTATED CDKN2A | TP53, CD74, HLA-C | PYGM 4109/4885SLC28A1 1444/4885SLC28A2 1251/4885 |
| US-12624104-B2 | Compositions and methods for treating cancer with anti-CD19 immunotherapy | CD2, CD22, CD4 | PYGM 4330/4885SLC28A1 2554/4885SLC28A2 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.